Twist Bioscience Corp

Twist Bioscience’s CEO sell‑to‑cover move shows routine liquidity, not a profit warning—insider trades hint at confidence amid rapid revenue growth and AI‑driven genomics expansion.

Insight: Twist CFO’s routine 3,000‑share sale spurs high buzz but signals neutral market impact; focus on biotech pipeline and growth prospects.

Twist Bioscience insider sell‑to‑cover: CFO Adam’s 2,738‑share sale post‑price surge shows routine tax compliance, not a red flag, and underscores the company’s synthetic‑DNA growth potential.